Your browser is no longer supported. Please, upgrade your browser.
Settings
CYCC Cyclacel Pharmaceuticals, Inc. daily Stock Chart
CYCC [NASD]
Cyclacel Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.59 Insider Own13.53% Shs Outstand16.49M Perf Week2.90%
Market Cap6.43M Forward P/E- EPS next Y-0.58 Insider Trans0.00% Shs Float14.48M Perf Month-7.12%
Income-7.90M PEG- EPS next Q-0.16 Inst Own16.30% Short Float2.24% Perf Quarter-29.86%
Sales0.20M P/S32.16 EPS this Y68.20% Inst Trans- Short Ratio4.41 Perf Half Y-47.28%
Book/sh0.91 P/B0.43 EPS next Y8.10% ROA-38.80% Target Price7.00 Perf Year-71.10%
Cash/sh0.92 P/C0.42 EPS next 5Y- ROE-48.60% 52W Range0.28 - 1.70 Perf YTD-35.52%
Dividend- P/FCF- EPS past 5Y47.50% ROI-53.70% 52W High-77.65% Beta2.99
Dividend %- Quick Ratio7.30 Sales past 5Y-32.70% Gross Margin- 52W Low35.09% ATR0.04
Employees14 Current Ratio7.30 Sales Q/Q- Oper. Margin- RSI (14)44.77 Volatility9.34% 11.15%
OptionableNo Debt/Eq0.00 EPS Q/Q32.80% Profit Margin- Rel Volume0.18 Prev Close0.39
ShortableYes LT Debt/Eq0.00 EarningsNov 12 AMC Payout- Avg Volume73.61K Price0.38
Recom1.70 SMA20-4.22% SMA50-11.59% SMA200-40.67% Volume2,262 Change-2.59%
Sep-07-18Initiated Ladenburg Thalmann Buy
Oct-16-15Initiated H.C. Wainwright Buy $5
Feb-04-10Initiated Roth Capital Buy $7
Oct-28-09Initiated Merriman Buy
Aug-12-08Initiated Piper Jaffray Buy $5
Mar-12-08Reiterated Needham & Co Buy $12 → $7
Mar-12-08Reiterated Collins Stewart Buy $12 → $13
Mar-12-08Reiterated Cantor Fitzgerald Buy $10.50 → $9
Nov-27-07Reiterated Cantor Fitzgerald Buy $14 → $10.50
Aug-10-07Reiterated Cantor Fitzgerald Buy $12 → $14
Jun-04-07Reiterated Needham & Co Buy $9 → $12
Apr-23-07Initiated Lazard Capital Buy $11
Apr-10-07Initiated Cantor Fitzgerald Buy $12
Oct-12-19 09:44AM  Here's Why We're Watching Cyclacel Pharmaceuticals's (NASDAQ:CYCC) Cash Burn Situation Simply Wall St.
Sep-23-19 07:00AM  Cyclacel Pharmaceuticals to Present at the Ladenburg Thalmann 2019 Healthcare Conference GlobeNewswire +7.16%
Sep-09-19 07:00AM  Cyclacel Pharmaceuticals Announces First Patient Treated With Oral CYC065 in a Phase 1 Study in Patients With Advanced Solid Tumors GlobeNewswire
Sep-04-19 07:00AM  Cyclacel Pharmaceuticals to Present at the 21st Annual H.C. Wainwright Global Investment Conference GlobeNewswire +10.52%
Sep-03-19 12:30PM  Edited Transcript of CYCC earnings conference call or presentation 13-Aug-19 8:30pm GMT Thomson Reuters StreetEvents -6.63%
Aug-28-19 12:34PM  Is Cyclacel Pharmaceuticals, Inc.'s (NASDAQ:CYCC) CEO Paid At A Competitive Rate? Simply Wall St. -5.22%
Aug-13-19 04:05PM  Cyclacel Pharmaceuticals Reports Second Quarter 2019 Financial Results GlobeNewswire -11.62%
07:25AM  The Daily Biotech Pulse: Jazz Goes Shopping, Portola Offering, Novelion Delays Quarterly Results Benzinga
Aug-11-19 03:46PM  The Week Ahead In Biotech: Vanda Awaits FDA Decision, BioVie Plans IPO Benzinga
Aug-07-19 07:00AM  Cyclacel Pharmaceuticals to Release Second Quarter 2019 Financial Results GlobeNewswire
Jul-22-19 07:00AM  Cyclacel Pharmaceuticals Announces First Patient Treated in a Phase 1/2 Study of Sapacitabine and Venetoclax in Relapsed or Refractory AML or MDS Patients GlobeNewswire
Jul-04-19 06:49AM  Edited Transcript of CYCC earnings conference call or presentation 14-May-19 8:30pm GMT Thomson Reuters StreetEvents
Jun-26-19 02:59PM  Some Cyclacel Pharmaceuticals (NASDAQ:CYCC) Shareholders Have Copped A 99% Share Price Wipe Out Simply Wall St.
May-24-19 12:50PM  A Look At Benzinga Pro's Most-Searched Tickers For May 24 Benzinga +22.26%
May-14-19 04:05PM  Cyclacel Pharmaceuticals Reports First Quarter 2019 Financial Results GlobeNewswire
May-08-19 07:00AM  Cyclacel Pharmaceuticals to Release First Quarter 2019 Financial Results GlobeNewswire
Apr-29-19 09:55AM  Could Cyclacel Pharmaceuticals, Inc.'s (NASDAQ:CYCC) Investor Composition Influence The Stock Price? Simply Wall St.
Apr-09-19 11:05AM  Edited Transcript of CYCC earnings conference call or presentation 27-Mar-19 8:30pm GMT Thomson Reuters StreetEvents
Apr-01-19 07:00AM  Cyclacel Announces Presentation of Phase 1 Data of Sapacitabine Regimen in Patients With BRCA Mutant Breast Cancer at AACR 2019 GlobeNewswire
Mar-27-19 04:05PM  Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results GlobeNewswire
07:52AM  The Daily Biotech Pulse: FDA Nod For Novartis, Jazz Positive Late-Stage Data For Sleep Disorder Drug, Genfit IPO Benzinga
Mar-26-19 12:46PM  Cyclacel Drops After Study Supporting Cancer Drug's Mechanism Of Action Benzinga
08:30AM  Cyclacel Provides Clinical Development Update and Growth Drivers for 2019 in New SNNLive Video Interview on StockNewsNow.com ACCESSWIRE
Mar-25-19 07:00AM  Publication Identifies Cyclin E as Key Resistance Pathway to Breast Cancer Treated by CDK4/6 Inhibitors and Thereby Amenable to Treatment by CYC065 CDK2/9 Inhibitor GlobeNewswire
Mar-20-19 07:00AM  Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2018 Financial Results GlobeNewswire +15.86%
Mar-13-19 07:00AM  Cyclacel to Participate in 31st Annual ROTH Conference March 18-19 GlobeNewswire
Mar-05-19 07:00AM  Cyclacel Announces Abstracts Selected for Presentation at the American Association for Cancer Research Annual Meeting 2019 GlobeNewswire
Feb-05-19 07:00AM  Cyclacel Pharmaceuticals to Present at the 2019 BIO CEO & Investor Conference GlobeNewswire
Jan-24-19 07:25AM  New Research: Key Drivers of Growth for Square, American International Group, PolyOne, Sonoco Products, Enviva Partners, LP, and Cyclacel Pharmaceuticals Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Jan-07-19 07:00AM  Cyclacel Pharmaceuticals Reviews 2018 Achievements and Announces Key Business Objectives for 2019 GlobeNewswire
Jan-03-19 11:11PM  Edited Transcript of CYCC earnings conference call or presentation 12-Nov-18 9:30pm GMT Thomson Reuters StreetEvents
Dec-27-18 07:00AM  Cyclacel Pharmaceuticals to Present at Biotech Showcase 2019 in San Francisco GlobeNewswire
Dec-25-18 02:25PM  Does Cyclacel Pharmaceuticals, Inc.s (NASDAQ:CYCC) CEO Pay Reflect Performance? Simply Wall St.
Dec-04-18 07:35AM  Consolidated Research: 2018 Summary Expectations for Xencor, Cyclacel Pharmaceuticals, Amicus Therapeutics, Take-Two Interactive Software, CSG Systems International, and Vonage Fundamental Analysis, Key Performance Indications GlobeNewswire
Nov-13-18 07:54AM  The Daily Biotech Pulse: Viking's Fatty Liver And Cholesterol Drug, Cyclacel Loss Narrows, Eton's Debut Benzinga
Nov-12-18 04:05PM  Cyclacel Pharmaceuticals Reports Third Quarter 2018 Financial Results GlobeNewswire
Nov-06-18 07:00AM  Cyclacel Pharmaceuticals to Release Third Quarter 2018 Financial Results GlobeNewswire
Oct-25-18 08:30AM  Report: Exploring Fundamental Drivers Behind Invitae, Aerie Pharmaceuticals, Gevo, Global Medical REIT, Cyclacel Pharmaceuticals, and Toll Brothers New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Oct-23-18 07:00AM  Cyclacel Pharmaceuticals to Present at the Dawson James Small Cap Growth Conference GlobeNewswire
Oct-04-18 07:00AM  Cyclacel Pharmaceuticals and MD Anderson Cancer Center Announce Strategic Alliance to Study Novel Cyclacel Medicines in Hematological Malignancies GlobeNewswire +6.60%
Sep-26-18 07:00AM  Cyclacel Pharmaceuticals to Present at the Ladenburg Thalmann 2018 Healthcare Conference GlobeNewswire
Sep-20-18 01:01PM  What does Cyclacel Pharmaceuticals Incs (NASDAQ:CYCC) Balance Sheet Tell Us About Its Future? Simply Wall St.
Sep-12-18 07:00AM  Cyclacel Pharmaceuticals Appoints Robert J. Spiegel, M.D. to Board of Directors GlobeNewswire -5.56%
Sep-10-18 07:00AM  Cyclacel Pharmaceuticals Announces Initiation of Phase 1b/2 Clinical Trial of Sapacitabine With Olaparib in BRCA Mutant Breast Cancer GlobeNewswire
Sep-05-18 07:30AM  Factors of Influence in 2018, Key Indicators and Opportunity within Aerie Pharmaceuticals, BioScrip, Celsion, Primoris Services, Cyclacel Pharmaceuticals, and Barnes Group New Research Emphasizes Economic Growth GlobeNewswire -5.73%
Aug-29-18 07:00AM  Cyclacel Pharmaceuticals to Present at the 20th Annual H.C. Wainwright Global Investment Conference GlobeNewswire
Aug-27-18 09:45PM  Edited Transcript of CYCC earnings conference call or presentation 9-Aug-18 8:30pm GMT Thomson Reuters StreetEvents
Aug-16-18 08:15AM  Investor Expectations to Drive Momentum within Global Medical REIT, Cyclacel Pharmaceuticals, Super Micro Computer, Kelly Services, Invitae, and ScanSource Discovering Underlying Factors of Influence GlobeNewswire
Aug-09-18 04:05PM  Cyclacel Pharmaceuticals Reports Second Quarter 2018 Financial Results GlobeNewswire
02:30PM  Cyclacel Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Aug-01-18 07:00AM  Cyclacel Pharmaceuticals to Release Second Quarter 2018 Financial Results GlobeNewswire
May-25-18 02:09PM  Who Really Owns Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC)? Simply Wall St.
May-21-18 05:23PM  Edited Transcript of CYCC earnings conference call or presentation 14-May-18 8:30pm GMT Thomson Reuters StreetEvents
May-14-18 04:05PM  Cyclacel Pharmaceuticals Reports First Quarter 2018 Financial Results GlobeNewswire
12:30PM  Cyclacel Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
10:51AM  Cyclacel Pharmaceuticals Incs (NASDAQ:CYCC) Earnings Dropped -23.81%, Did Its Industry Show Weakness Too? Simply Wall St.
May-08-18 07:00AM  Cyclacel Pharmaceuticals to Release First Quarter 2018 Financial Results GlobeNewswire
May-04-18 08:10AM  Recent Analysis Shows Lancaster Colony, Calavo Growers, Acuity Brands, Cyclacel Pharmaceuticals, Enbridge Energy Management, and Nasdaq Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Apr-17-18 09:00AM  Cyclacels CYC065 CDK Inhibitor Demonstrates Synergy With Venetoclax By Dual Targeting Of Chronic Lymphocytic Leukemia GlobeNewswire -5.23%
Apr-16-18 07:00AM  Cyclacel Announces Presentation of Phase 1 Clinical Data for CDK Inhibitor CYC065 at AACR 2018 Annual Meeting GlobeNewswire -8.28%
Apr-13-18 11:38AM  The Week Ahead In Biotech: PDUFA Dates, IPOs And More Benzinga
Apr-09-18 07:10AM  Wired News Stemline Therapeutics Initiates Rolling BLA Submission for SL-401 ACCESSWIRE
Mar-29-18 01:16PM  Edited Transcript of CYCC earnings conference call or presentation 28-Mar-18 8:30pm GMT Thomson Reuters StreetEvents
Mar-28-18 04:05PM  Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results GlobeNewswire
12:30PM  Cyclacel Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Mar-21-18 07:00AM  Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2017 Financial Results GlobeNewswire
Mar-20-18 07:45AM  Consolidated Research: 2018 Summary Expectations for Triangle Capital, Federal Agricultural Mortgage, Cyclacel Pharmaceuticals, Sterling Construction, Select Energy Services, and Citi Trends Fundamental Analysis, Key Performance Indications GlobeNewswire
Mar-15-18 07:00AM  Phase 1 Clinical Data With Cyclacels CYC065 CDK Inhibitor Have Been Selected for Oral Presentation at AACR 2018 Annual Meeting GlobeNewswire
Mar-06-18 07:19AM  Cyclacel Pharmaceuticals to Present at the 30th Annual ROTH Conference GlobeNewswire
Feb-21-18 07:00AM  Cyclacel Announces Notice of Grant of New European Patent Covering Sapacitabine Pharmaceutical Formulations GlobeNewswire
Feb-06-18 07:00AM  Cyclacel Pharmaceuticals to Present at the 2018 BIO CEO & Investor Conference GlobeNewswire
Feb-05-18 06:29PM  Should You Be Concerned About Cyclacel Pharmaceuticals Incs (NASDAQ:CYCC) Shareholders? Simply Wall St.
Jan-24-18 07:00AM  Cyclacel Pharmaceuticals to Present at the Noble Capital Markets Investor Conference GlobeNewswire
Jan-19-18 07:55PM  Cyclacel Pharmaceuticals Incs (NASDAQ:CYCC) Earnings Declined -24.93%, But How Did It Fare Against The Industry? Simply Wall St.
Jan-18-18 08:20AM  New Research Coverage Highlights Cyclacel Pharmaceuticals, American Assets Trust, Roper Technologies, Central Garden & Pet, Home, and Tompkins Financial Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Jan-09-18 07:00AM  Cyclacel Reviews 2017 Achievements and Announces Key Business Objectives for 2018 GlobeNewswire
Jan-02-18 01:09PM  What You Must Know About Cyclacel Pharmaceuticals Incs (NASDAQ:CYCC) Financial Health Simply Wall St.
Dec-13-17 01:06PM  ETFs with exposure to Cyclacel Pharmaceuticals, Inc. : December 13, 2017 Capital Cube
Dec-12-17 07:00AM  Cyclacel Announces Presentation of Results From Phase 3 Seamless Study at Ash Annual Meeting GlobeNewswire -9.98%
Nov-27-17 01:02PM  ETFs with exposure to Cyclacel Pharmaceuticals, Inc. : November 27, 2017 Capital Cube
Nov-22-17 02:05AM  Edited Transcript of CYCC earnings conference call or presentation 9-Nov-17 9:30pm GMT Thomson Reuters StreetEvents
Nov-09-17 04:05PM  Cyclacel Pharmaceuticals Reports Third Quarter 2017 Financial Results GlobeNewswire
Nov-02-17 07:00AM  Cyclacel Pharmaceuticals to Release Third Quarter 2017 Financial Results GlobeNewswire
Nov-01-17 09:02AM  Cyclacel Pharmaceuticals Announces That Full Results From the Phase 3 Seamless Trial Have Been Selected for Oral Presentation at ASH 2017 Annual Meeting GlobeNewswire
Oct-16-17 10:49AM  The Week Ahead: Earnings, Earnings, And More Earnings Benzinga
Sep-21-17 07:00AM  Cyclacel Pharmaceuticals to Present at the Ladenburg Thalmann 2017 Healthcare Conference GlobeNewswire
Sep-13-17 08:00AM  Today's Research Reports on Trending Tickers: Cyclacel Pharmaceuticals and MannKind Corporation ACCESSWIRE
Sep-08-17 07:00AM  Cyclacel Pharmaceuticals to Present at the 19th Annual Rodman & Renshaw Global Investment Conference GlobeNewswire
Aug-16-17 08:11PM  Edited Transcript of CYCC earnings conference call or presentation 9-Aug-17 8:30pm GMT Thomson Reuters StreetEvents
07:20AM  Featured Company News - Soligenix Receives $2.5 million in Additional NIAID Funding to Advance Development of Heat Stable Ricin Vaccine ACCESSWIRE
Aug-09-17 04:05PM  Cyclacel Pharmaceuticals Reports Second Quarter 2017 Financial Results GlobeNewswire
12:00PM  Investor Network: Cyclacel Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Aug-07-17 07:00AM  Cyclacel Announces Selection of Recommended Phase 2 Dose for CYC065 and Evidence of Durable Target Engagement and Mcl-1 Biomarker Suppression GlobeNewswire
Aug-02-17 07:00AM  Cyclacel Pharmaceuticals to Release Second Quarter 2017 Financial Results GlobeNewswire
Jul-21-17 02:00PM  Cyclacel Announces Closing of $15.2 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option GlobeNewswire
Jul-20-17 08:10AM  Today's Research Reports on Trending Tickers: Cyclacel Pharmaceuticals Inc. and Canadian Solar Inc. Accesswire
May-19-17 11:05AM  Edited Transcript of CYCC earnings conference call or presentation 11-May-17 8:30pm GMT Thomson Reuters StreetEvents
May-11-17 07:16PM  Edited Transcript of CYCC earnings conference call or presentation 11-May-17 8:30pm GMT Thomson Reuters StreetEvents
04:05PM  Cyclacel Pharmaceuticals Reports First Quarter 2017 Financial Results GlobeNewswire
12:00PM  Investor Network: Cyclacel Pharmaceuticals, Inc. to Host Earnings Call Accesswire
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's oncology development programs include CYC065, a cyclin dependent kinase Inhibitors (CDK) that is in Phase I clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase I clinical trial for the treatment of advanced leukemias. Its oncology development programs also comprise sapacitabine, an oral nucleoside analogue prodrug that is in Phase 1/2 combination study with seliciclib, a CDK inhibitor in patients with BRCA mutations; with olaparib, a poly ADP-ribose polymerase inhibitor in BRCA mutation positive patients with breast cancer; and Phase III clinical trial for the treatment of acute myeloid leukemia. In addition, the company's oncology development programs include seliciclib, a CDK inhibitor that is in all-oral Phase 1/2 combination study with sapacitabine for BRCA mutations. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias; and collaboration, licensing, and supply agreement with ManRos Therapeutics SA for the development and commercialization of oral seliciclib capsules for the treatment of cystic fibrosis. Cyclacel Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Berkeley Heights, New Jersey.